BPC-157 doses in studies: what researchers actually used

Researchers have used BPC-157 in very different amounts: micrograms per kilogram in rats, and milligrams in a few small human reports. These doses come from animal work, one trial known only as an abstract, and a two-person safety pilot, so they do not show what is safe or what works in people.^[1][2][3]

This post lists what was used. It is not advice to take anything.

What rats and mice received

Most BPC-157 research is in animals, and much of it comes from one research group.^[2]

• Achilles tendon cut in rats: 10 µg/kg, 10 ng/kg or 10 pg/kg intraperitoneally, once daily from 30 minutes after surgery, for up to 14 days.^[1]
• Achilles transection and repair in rats: 10 µg/kg/day intraperitoneally for 4 weeks, alone or combined with TB-500 60 µg/kg/day.^[4]
• Hind-limb ischaemia-reperfusion in rats: 20 µg/kg intraperitoneally.^[5]

The first study came from the group that originated the compound. It reported better load to failure, walking function and tendon structure.^[1]

A 2026 study by a different group used 32 rats, 8 per group. Load to failure was higher than in controls but not significantly. The TB-500 group, not the BPC-157 group, reached significance.^[4]

What people received

Human data are thin. Here is every dose our sources describe.

• Ulcerative colitis trial: 53 adults with mild-to-moderate disease got an 80 mg BPC-157 enema or placebo once daily for 2 weeks. This is a 2005 meeting abstract as summarised by FDA.^[2]
• IV safety pilot: 2 adults, ages 58 and 68, got 10 mg on day 1 and 20 mg on day 2, each in 250 mL saline over one hour.^[3]
• Knee pain chart review: 17 people were treated at one private clinic. The abstract gives no dose. FDA's briefing lists 2 to 4 mg injected into the knee, 1 to 2 times.^[6][2]
• A trial registered for 2027 will test daily subcutaneous BPC-157 for 90 days after rotator cuff repair. It is phase 1, plans 30 participants and is not yet recruiting. Our sources don't cover its dose.^[7]

What those human results showed

In the colitis trial, the disease score fell by 3.2 points with BPC-157 and 1.6 with placebo. The difference between groups had a 95% CI of -4.84 to 1.62, so it did not exclude no effect. FDA called the data inadequate to support efficacy or safety.^[2]

In the knee review, 14 of 16 people reached by phone reported pain relief. There was no control group and no validated outcome tool. Recall was 6 to 12 months later.^[6]

In the IV pilot, the authors reported no change in blood tests and no side effects. Two people over 3 days cannot establish safety.^[3]

Why these numbers are not a dosing guide

• The rat doses span a huge range, from 10 pg/kg to 10 µg/kg, and all were reported to help in one study. FDA's reviewers noted that dose-response relationships have not been established.^[1][2]
• Rat doses are given per kilogram. Human doses above are total amounts per administration. The routes also differ: intraperitoneal, enema, IV and knee injection.^[1][2][3]
• FDA said there is no information on BPC-157 pharmacokinetics in humans.^[2]
• In animals, intramuscular bioavailability was about 14 to 19% in rats and 45 to 51% in dogs. Half-life was under 30 minutes.^[8][9]
• Product quality sold online is unknown. A review of the orthopaedic literature warns of unregulated manufacturing and contamination.^[10]

Safety and regulatory context

FDA's reviewers found no studies of oral, subcutaneous, nasal or skin use in people. They found only two rectal-enema studies of up to 2 weeks, with limited safety monitoring.^[2]

Reports to FDA's adverse event system included injection site reaction, shortness of breath, and gum and skin darkening. FDA said it was unclear whether BPC-157 caused them.^[2]

No approved drug contains BPC-157 in any country.^[2] FDA's briefing document proposed not adding it to the 503A bulks list.^[2] An advisory committee reportedly voted narrowly the other way. That vote is advisory and non-binding.^[11]

The bottom line

Doses in the studies range from picograms per kilogram in rats to 80 mg as an enema in one human trial.^[1][2]

The human trial did not show a clear benefit, and the other human reports are a chart review and a two-person pilot.^[2][6][3]

The animal work is mostly from one group and has few independent replications.^[4][2]

No one has established an effective or safe dose for people. If you are weighing BPC-157, bring this evidence to a clinician who knows your health history.